Drugs.com - New Drug Approvals

FDA Grants Accelerated Approval to Bizengri (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics...

Feb 9, 2025 - 22:25
 0
FDA Grants Accelerated Approval to Bizengri (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics...
Read More

Tags:

Previous Article

Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients ...

Next Article

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara

Related Posts

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Incyte and Syndax Announce U.S. Food and Drug Administr...

Feb 9, 2025  0

FDA Approves Symvess (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

FDA Approves Symvess (acellular tissue engineered vesse...

Feb 9, 2025  0

FDA Approves Leqembi (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves Leqembi (lecanemab-irmb) IV Maintenance Do...

Feb 9, 2025  0